AIM
RXRX icon

Anchor Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Anchor Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06K Hold
347
– – ﹤0.01% 1021
2025
Q4 		$1.42K Hold
347
– – ﹤0.01% 993
2025
Q3 		$1.69K Hold
347
– – ﹤0.01% 995
2025
Q2 		$1.76K Hold
347
– – ﹤0.01% 969
2025
Q1 		$1.84K Hold
347
– – ﹤0.01% 956
2024
Q4 		$2.35K Buy
+347
New +$2.33K ﹤0.01% 930

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Anchor Investment Management's RXRX Position: Q1 2026 in Review

Anchor Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 347 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1021.

Anchor Investment Management first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.35K in Q4 2024. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Anchor Investment Management held 347 shares of Recursion Pharmaceuticals worth $1.06K as of Q1 2026.
  • Anchor Investment Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Anchor Investment Management's portfolio in Q1 2026, its #1021 holding.
  • Anchor Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Anchor Investment Management's Recursion Pharmaceuticals position peaked at $2.35K in Q4 2024.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Anchor Investment Management's 13F filing for Q1 2026, filed 1 May 2026.